Table 4 AEs during 30-day follow-up
Characteristic | Omeprazole group (n = 303) | Pantoprazole group (n = 304) | P value |
|---|---|---|---|
Stent thrombosis [n (%)] | 0 | 1 (0.3) | 1.00 |
MACEs [n (%)] | 7 (2.3) | 5 (1.6) | 0.58 |
Cardiac death | 1 (0.3) | 0 | 0.50 |
Myocardial infarction | 0 | 0 | — |
Ischemic symptoms driven target vessel revascularization | 1 (0.3) | 0 | 0.50 |
Non-target vessel revascularization | 5 (1.7) | 5 (1.6) | 1.00 |
Recurrent angina [n (%)] | 19 (6.3) | 12 (3.9) | 0.20 |
All-cause death [n (%)] | 1 (0.3)a | 0 | 0.50 |
TIMI bleeding events [n (%)] | |||
Major | 0 | 0 | — |
Moderate | 0 | 0 | — |
Minor | 4 (1.3) | 8 (2.6) | 0.38 |
Stroke [n (%)] | 0 | 0 | — |
Adverse drug reactions [n (%)] | 23 (7.6) | 29 (9.5) | 0.47 |
AEs [n (%)] | 46 (15.2) | 45 (14.8) | 0.91 |